Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Castle Creek Biosciences LLC manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio's prosecution is distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's active matters are being handled independently by different sections of the patent office. This diversified approach can provide multiple paths to allowance but also requires managing different examiner expectations and art unit standards simultaneously.
The busiest examiner, VIVLEMORE, TRACY ANN, is responsible for 1 busiest examiner pending action. Because the total number of 2 pending office actions is distributed among 2 distinct examiners, each examiner is currently handling a specific matter. Practitioners must develop separate strategies for each of the pending matters, as they are being reviewed by different individuals in different art units, each with their own specific procedural requirements and technical focuses. The presence of 2 distinct art units suggests the company's technology may span different biological or pharmaceutical classifications, requiring a broader range of expertise from the legal team.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.4% |
| NGUYEN, QUANG | 1 | 37.9% | +52.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18079358 | Dosage Unit Formulations Of Autologous Dermal Fibroblasts | VIVLEMORE, TRACY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16086151 | COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE VII COLLAGEN DEFICIENCIES | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18079358 | Dosage Unit Formulations Of Autologous Dermal Fibroblasts | VIVLEMORE, TRACY ANN | 1638 | §101§103§112 | Final Rejection | — | Pending | Dec 12, 2022 |
| 16086151 | COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE VII COLLAGEN DEFICIENCIES | NGUYEN, QUANG | 1631 | §112 | Non-Final OA | — | Pending | Sep 18, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCastle Creek Biosciences LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Tracy Ann Vivlemore has the most, with 1 of Castle Creek Biosciences LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
